Contributors
Jonathan S. Abramowitz(University of North Carolina at Chapel Hill), Patrick F. Sullivan(University of North Carolina at Chapel Hill), Mary Kimmel(University of North Carolina at Chapel Hill), Karen Putnam(University of North Carolina at Chapel Hill), Jerry Guintivano(University of North Carolina at Chapel Hill), Zachary Kaminsky(University of Ottawa), Megan M. Hare(Florida International University), Jack Samuels(University of Iowa), Jamie Maguire(Tufts University), Samantha Meltzer‐Brody(University of North Carolina at Chapel Hill), Christy Duan(Northwell Health), Liisa Hantsoo(Johns Hopkins University), Lindsay R. Standeven(Johns Hopkins University), Samantha N. Hellberg(University of North Carolina at Chapel Hill), Jennifer L. Payne(University of the Virgin Islands), Gerald Nestadt(Behavioral Pharma (United States)), Kristina M. Deligiannidis(Zucker Hillside Hospital), Jennifer L. Buchholz(University of North Carolina at Chapel Hill), Katherine McEvoy(Johns Hopkins University), Arianna Di Florio(University of North Carolina at Chapel Hill), Lauren M. Osborne(Johns Hopkins University)
Cited by 0
Related Papers
Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia
|The American Journal of Human Genetics|2003|1.1k
Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
|The Lancet|2018|780
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial
|The Lancet|2017|474
Association of depression with 10-year poststroke mortality
|American Journal of Psychiatry|1993|472